Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Drops By 93.8%

Xenetic Biosciences Inc (NASDAQ:XBIO) saw a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 500 shares, a decrease of 93.8% from the November 30th total of 8,100 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 24,400 shares, the short-interest ratio is presently 0.0 days.

Xenetic Biosciences Stock Performance

Xenetic Biosciences stock opened at $4.04 on Friday. The firm has a market capitalization of $6.23 million, a P/E ratio of -1.52 and a beta of 2.24. The company has a 50-day simple moving average of $4.02 and a 200-day simple moving average of $3.98. Xenetic Biosciences has a one year low of $2.78 and a one year high of $5.20.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14). Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. The business had revenue of $0.61 million for the quarter, compared to the consensus estimate of $0.75 million. As a group, sell-side analysts forecast that Xenetic Biosciences will post -1.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Xenetic Biosciences in a report on Thursday, December 5th.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.